SUBSCRIBE
SUBSCRIBE

Alkermes

NEWS
Policy
FDA Eyes Safety Of Popular Anemia Drugs
October 19, 2005
 · 
1 min read
Business
ConjuChem
October 19, 2005
 · 
8 min read
Biotech Moves Ahead Of Major Indexes
October 19, 2005
 · 
1 min read
Load More
JOBS
IN THE PRESS
Press Releases
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
February 25, 2026
 · 
1 min read
Press Releases
Alkermes plc Announces CEO Succession Plan
February 25, 2026
 · 
9 min read
Press Releases
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
February 25, 2026
 · 
1 min read
Press Releases
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
February 12, 2026
 · 
13 min read
Press Releases
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
February 12, 2026
 · 
1 min read
Press Releases
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
January 6, 2026
 · 
5 min read
Press Releases
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 30, 2025
 · 
1 min read
Press Releases
Alkermes to Participate in Two Upcoming December 2025 Investor Conferences
November 26, 2025
 · 
1 min read
Press Releases
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
November 13, 2025
 · 
11 min read
Press Releases
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
July 21, 2025
 · 
11 min read
Load More